Press Releases Processa Pharmaceuticals, Inc.

Equities

PCSA

US74275C3043

Market Closed - Nasdaq Other stock markets 04:30:00 2024-07-05 pm EDT			5-day change	1st Jan Change
1.73 ^USD	-4.42%		-22.77%	-74.15%

Jun. 11	Processa Pharmaceuticals, Inc. Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1B Dose-Escalating Trial with Ngc-Cap in Gastrointestinal Cancer	CI
Jun. 07	Top Premarket Decliners	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer	Jun. 11	AQ
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference	May. 06	AQ
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research	Apr. 30	AQ
Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial	Apr. 11	AQ
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference	Mar. 28	AQ
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting	Mar. 25	AQ
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference	Feb. 21	AQ
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference	Feb. 14	AQ
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule	Feb. 06	AQ
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering	Feb. 01	AQ
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI	Jan. 30	AQ
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering	Jan. 26	GL
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses	Jan. 25	AQ
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer	Jan. 19	AQ
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split	Jan. 18	AQ
Processa Pharmaceuticals to Present at the Biotech Showcase 2024	Jan. 02	AQ
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine	Dec. 19	AQ
Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine	Dec. 13	AQ
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference	Nov. 30	AQ
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook	Nov. 29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Processa Pharmaceuticals, Inc.

Equities

PCSA

US74275C3043

Press Releases

Filters